Teduglutide

Teduglutide — ADMETatlas

Computed descriptors

Core descriptors33 aa · pI 4.0 · GRAVY -0.35

Length: 33 aa
Monoisotopic mass: 3749.80 Da
Average mass: 3752.13 Da
Net charge at pH 7.4: -3.90
Estimated pI: 4.01
GRAVY: -0.348
KD-positive residues: 36.4%
Aromatic residues: 9.1%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.40
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

3.91

pH 5

-2.51

pH 6

-3.19

pH 7.4

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

13-19

ILDNLAA

GRAVY 1.243

Most hydrophilic window

3-9

DGSFSDE

GRAVY -1.386

27 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asn deamidation motif

NT · pos 11

Asn followed by small/polar residues is a known sequence context to review for deamidation susceptibility.

Asp isomerization motif

DG · pos 3

Asp-containing motifs can merit review for isomerization or related degradation pathways.

Oxidation-sensitive residues

M, W · pos 10, 25

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.40100°/residue · 33 aa

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

5. Exposure / Absorption

What evidence describes systemic exposure or absorption?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Bioavailability Tmax Cmax AUC

Bioavailability, AUC, Cmax, and Tmax evidence.

Evidence interpretation

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability3 measurements · 3 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	88 %	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · bioavailability single percent · 12.3 Pharmacokineti...	Open
2	88 %	Comparable	Oral bioavailability in human · human	Route: oral · bioavailability · F· Oral bioavailability in human · Exact ChEMBL pref name TEDUGLUTIDE ·...	Open
3	88 %	Comparable	PepTherDia curated product PK field	Route: SC · 17 · Teduglutide · exact product name match · field mismatch	Open

Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.

6. Distribution / Barrier

What is known about distribution, binding, permeability, or barrier crossing?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Vd Plasma protein binding

Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd3 measurements · 3 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	103 mL/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Teduglutide· 12.3 Pharmacokinetics · volume of distribution parenthetical · Distribution...	Open
2	103 mL/kg	Comparable	THPdb curated therapeutic product PK entry	Route: Subcutaneous · Th1137 · Teduglutide · single value · Subcutaneous · N.A. · 1 · 1624 · US5789379 · 2016-1...	Open
3	103 mL/kg	Comparable	THPdb curated therapeutic product PK entry	Th1137 · Teduglutide · single value · N.A. · N.A. · 2 · 1625\|1626 · US7056886 · 2016-12-22	Open

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.

7. Metabolic & Proteolytic Stability

How stable is the peptide in biological matrices or protease systems?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Serum/plasma stability

Serum/plasma stability and protease stability evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability13 measurements · 13 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.6 ± 0.1 Hours 2160 seconds	Comparable	GLP-2 ELISA · rat · SD rats serum	Route: SC · Dose/window: 670 nmol/kg · Time: Blood (0.3 ml) was then collected from the jugularvein at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours for tedu... · SD rats serum protease · In Vivo	Open
2	25 Minutes 1500 seconds	Comparable	In vitro cell based activity assay · mouse · Mice plasma	Route: IV · Dose/window: 10 nmol/kg · Time: Plasma levels of the peptides at various time points (5 min, 30 min, 1 h, 3 h, 7 h, and 24 h) · Mice plasma protease · In Vivo	Open
3	3240 seconds	Comparable	LC-MS/MS · monkey · Male cynomolgus monkeys plasma	Dose/window: 0.25 mg/kg · Time: Blood samples were collected at multiple time points up to 169 h post injection · Male cynomolgus monkeys plasma protease · In Vivo	Open
4	5280 seconds	Comparable	LC-MS/MS · porcine · Göttingen minipigs plasma	Dose/window: 0.100 mg/kg · Time: Blood samples were collected at multiple time points up to 6 h post injection · Göttingen minipigs plasma protease · In Vivo	Open
5	9720 seconds	Comparable	LC-MS/MS · porcine · Göttingen minipigs plasma	Dose/window: 0.15 mg/kg · Time: Blood samples were collected at multiple time points up to 169 h post injection · Göttingen minipigs plasma protease · In Vivo	Open
6	960 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Dose/window: 0.2 mg/kg · Time: Blood samples were collected at multiple time points up to 6 h post injection · Rats plasma protease · In Vivo	Open
7	1800 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Dose/window: 1 mg/kg · Time: Blood samples were collected at multiple time points up to 169 h post injection · Rats plasma protease · In Vivo	Open
8	1800 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Dose/window: 5 mg/kg · Time: Blood samples were collected at multiple time points up to 169 h post injection · Rats plasma protease · In Vivo	Open
9	5832 seconds	Comparable	modified · rat · Rats plasma	Dose/window: 2 mg/mL · Time: Blood samples were collected from the tail vein at 0, 1, 2, 3, 4, 5,6, 9 and 12 h after administration · Rats plasma protease · In Vivo	Open
10	1.1 Hours 3960.0000000000005 seconds	Comparable	natural · human · Human adult plasma (in Japanese patients with SBS)	Route: SC · Dose/window: 0.05 mg/kg · Human plasma protease · In Vivo	Open

1–10 / 13

Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.

8. Excretion / Persistence

What evidence describes clearance or persistence?

Evidence summary

Measurements

Measurements, observations, and support attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Comparable measurements

Rows suitable for comparison only within matching endpoint and assay context.

Reported observations

Reviewed observations retained without being collapsed into comparable values.

Domain scope

Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.

Clearance

Clearance and half-life evidence.

Evidence interpretation

The same three research-facing layers are used across ADMETatlas.

Comparable measurements

Endpoint-ready rows with structured values and assay context.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance4 measurements · 4 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	~ 123 mL/h/kg	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Teduglutide· 12.3 Pharmacokinetics · clearance single · Excretion In healthy subjects, te...	Open
2	13 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table clf mean · Table 2: Tedu...	Open
3	7.45 L/h	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table clf mean · Table 2: Tedu...	Open
4	9.9 mL/min/kg	Comparable	Systemic clearance in Sprague-Dawley rat at 0.2 mg/kg, iv through cassette dosing measured up to 300 mins by LC/MS/MS analysis · rat	Route: iv · clearance · CL· Systemic clearance in Sprague-Dawley rat at 0.2 mg/kg, iv through cassett...	Open

Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.

Evidence landscape and measurement index

Evidence landscape

A cross-domain view of where evidence is concentrated, which interpretation layers dominate, and how traceable the measurements are.

ADMET domain

Comparable

Reported

Contextual

Exposure / Absorption

12 measurements

Distribution / Barrier

4 measurements

Metabolic & Proteolytic Stability

13 measurements

Excretion / Persistence

4 measurements

Toxicity / Safety

0 measurements

Endpoint distribution

Top evidence-bearing endpoint questions.

Serum Plasma Stability

Area Under Curve

Clearance

Max Concentration

Bioavailability

Volume Of Distribution

Plasma Protein Binding

Time To Max Concentration

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Clinical / product

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every measurement remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainLayerReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Evidence layer	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	9,720 seconds	Comparable	LC-MS/MS · porcine · Göttingen minipigs plasma	Time: Blood samples were collected at multiple time points up to 169 h post injection · Dose/window: 0.15 mg/kg · Protease: Göttingen minipigs plasma protease · In Vivo	Open
2	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.6 ± 0.1 Hours 2,160 seconds	Comparable	GLP-2 ELISA · rat · SD rats serum	Route: SC · Time: Blood (0.3 ml) was then collected from the jugularvein at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours for teduglutide and 1, 4, 8, 24, 48, 72, 96, 230, 244, 268, 192, 216,...	Open
3	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	5,280 seconds	Comparable	LC-MS/MS · porcine · Göttingen minipigs plasma	Time: Blood samples were collected at multiple time points up to 6 h post injection · Dose/window: 0.100 mg/kg · Protease: Göttingen minipigs plasma protease · In Vivo	Open
4	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	5,832 seconds	Comparable	modified · rat · Rats plasma	Time: Blood samples were collected from the tail vein at 0, 1, 2, 3, 4, 5,6, 9 and 12 h after administration · Dose/window: 2 mg/mL · Protease: Rats plasma protease · In Vivo	Open
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.89 Hours 3,204 seconds	Comparable	natural · human · Human pediatrics plasma (in Japanese patients with SBS)	Route: SC · Dose/window: 0.05 mg/kg · Protease: Human plasma protease · In Vivo	Open
6	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1,800 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Time: Blood samples were collected at multiple time points up to 169 h post injection · Dose/window: 5 mg/kg · Protease: Rats plasma protease · In Vivo	Open
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1,800 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Time: Blood samples were collected at multiple time points up to 169 h post injection · Dose/window: 1 mg/kg · Protease: Rats plasma protease · In Vivo	Open
8	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	960 seconds	Comparable	LC-MS/MS · rat · Rats plasma	Time: Blood samples were collected at multiple time points up to 6 h post injection · Dose/window: 0.2 mg/kg · Protease: Rats plasma protease · In Vivo	Open
9	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1.1 Hours 3,960 seconds	Comparable	natural · human · Human adult plasma (in Japanese patients with SBS)	Route: SC · Dose/window: 0.05 mg/kg · Protease: Human plasma protease · In Vivo	Open
10	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	25 Minutes 1,500 seconds	Comparable	In vitro cell based activity assay · mouse · Mice plasma	Route: IV · Time: Plasma levels of the peptides at various time points (5 min, 30 min, 1 h, 3 h, 7 h, and 24 h) · Dose/window: 10 nmol/kg · Protease: Mice plasma protease · In Vivo	Open

1–10 / 33

Identity & reference map

Summary10 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 10
Measurements: 33
ATL peptide ID: ATLPC0010824

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

14 / 14

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 14

Different notation

Reported notation does not resolve to the current display sequence.

0 / 14

Reference map10 of 10 shown

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference link Open	DistributionExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +2 more	No reported alias	0 identity 14 evidence
PubMed 32075870 Open	Stability Serum Plasma Stability	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	6 identity 6 evidence
PubMed 34402197 Open	Stability Serum Plasma Stability	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	4 identity 4 evidence
Reference link Open	Distribution Volume Of Distribution	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	1 identity 2 evidence
PubMed 36410792 Open	Stability Serum Plasma Stability	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	1 identity 1 evidence
PubMed 28522195 Open	Stability Serum Plasma Stability	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	1 identity 1 evidence
PubMed 29528634 Open	Stability Serum Plasma Stability	No reported alias HGDGSFSDEMNTILDNLAARDFINWLIQTKITDexact	1 identity 1 evidence
PubMed 26986178 Open	DistributionPersistence Clearance, Plasma Protein Binding	No reported alias	0 identity 2 evidence
Reference link Open	Exposure Bioavailability	No reported alias	0 identity 1 evidence
PubMed 38691890 Open	Exposure Bioavailability	No reported alias	0 identity 1 evidence

Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.

Data access & reproducibility

Record scopePublic release

ATL peptide ID: ATLPC0010824
Identity type: canonical sequence
ADMET endpoints: 8
Measurements: 33
Reference groups: 10
Release view: Public release

Analysis-ready files

Peptide record

TSV

Identity, sequence, profile-level fields, and current release view metadata.

Download record

Programmatic access

The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.

Open endpoint

GET /api/v1/peptides/ATLPC0010824

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0010824' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.

#	Value	Evidence layer	Assay / model	Condition	Reference
1	0.15 μg*h/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · auc was value · Following a 0.05 mg/kg subcutaneous...	Open
2	154 ng*h/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table auc ss mean · Table 2: T...	Open
3	128 ng*h/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table auc ss mean · Table 2: T...	Open
4	Observation The C max and AUC of teduglutide was dose proportional over the dose range of 0.05 to 0.4 mg/kg (up to 8 times the recommended dose of GATTEX).	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Teduglutide· 12.3 Pharmacokinetics · cmax auc dose proportionality text · The C max and A...	Open

Cmax4 measurements · 3 comparable · 1 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	36 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · cmax was value · Following a 0.05 mg/kg subcutaneous...	Open
2	29.7 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table cmax ss mean · Table 2:...	Open
3	33.5 ng/mL	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · teduglutide age group table cmax ss mean · Table 2:...	Open
4	Observation The C max and AUC of teduglutide was dose proportional over the dose range of 0.05 to 0.4 mg/kg (up to 8 times the recommended dose of GATTEX).	Reported	DailyMed SPL 12.3 Pharmacokinetics label extraction · human	Teduglutide· 12.3 Pharmacokinetics · cmax auc dose proportionality text · The C max and A...	Open

Tmax1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	3-5 hours 10800-18000 seconds	Comparable	DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma	Route: subcutaneous · Teduglutide· 12.3 Pharmacokinetics · tmax range reached maximum · 12.3 Pharmacokinetics A...	Open

Plasma protein binding1 measurement · 1 comparable · 0 reported · 0 contextual

#	Value	Evidence layer	Assay / model	Condition	Reference
1	58.1 %	Comparable	Protein binding in rat plasma at 200 to 1000 ng/ml incubated for 15 mins by LC/MS/MS based ultracentrifugation method · rat · plasma	plasma protein binding · PPB· Protein binding in rat plasma at 200 to 1000 ng/ml incubate...	Open

Teduglutide

Peptide developability profile

1. Sequence & peptidoform

Sequence interpretation

2. Structure & chemistry

Structure and chemistry interpretation

3. Physicochemical profile

Computed descriptors

Computed developability descriptors

4. Product context

Translational product context

5. Exposure / Absorption

Evidence summary

6. Distribution / Barrier

Evidence summary

7. Metabolic & Proteolytic Stability

Evidence summary

8. Excretion / Persistence

Evidence summary

9. Evidence landscape

Evidence landscape and measurement index

10. Identity & reference map

Identity & reference map

11. Data access & reproducibility

Data access & reproducibility

Peptide record

Evidence table

Structured record